Paula Soteropoulos
Known title: DirectorCIK: 0001692444
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
QURE shares fall after Huntington data update and Barclays downgrade. Cedar Grove Capital released its Q3 2026 portfolio update, noting QURE holdings. The stock fell 5.9% after Huntington's gene therapy data was updated, prompting a Barclays downgrade to equal‑weight and a new price target of $28. The move comes amid a broader market pullback, with the shares near a 17.1 RSI and a support level of $44.06.
Transaction History
| DNTH | ▲ Buy | Option Exercise | 599 | $5K | 5/8/2026 | View on chart |
| DNTH | ▼ Sell | Open Market | 599 | $51K | 5/8/2026 | View on chart |
| DNTH | ▼ Sell | Open Market | 599 | $48K | 3/31/2026 | View on chart |
| DNTH | ▲ Buy | Option Exercise | 599 | $5K | 3/31/2026 | View on chart |
| DNTH | ▲ Buy | Option Exercise | 27,594 | $233K | 3/24/2026 | View on chart |
| DNTH | ▼ Sell | Open Market | 27,594 | $2.2M | 3/24/2026 | View on chart |
| QURE | ▼ Sell | Open Market | 2,220 | $11K | 6/13/2024 | View on chart |
| QURE | ▼ Sell | Open Market | 2,275 | $43K | 6/16/2023 | View on chart |
| QURE | ▲ Buy | Grant | 8,700 | $0 | 6/13/2023 | View on chart |
| QURE | ▼ Sell | Open Market | 384 | $8K | 2/27/2023 | View on chart |
| QURE | ▲ Buy | Option Exercise | 6,000 | $32K | 1/18/2023 | View on chart |
| QURE | ▼ Sell | Open Market | 6,000 | $136K | 1/18/2023 | View on chart |
| QURE | ▲ Buy | Option Exercise | 3,800 | — | 12/14/2022 | View on chart |
| QURE | ▼ Sell | Open Market | 3,800 | $89K | 12/14/2022 | View on chart |
| QURE | ▲ Buy | Option Exercise | 3,000 | $16K | 12/13/2022 | View on chart |
| QURE | ▼ Sell | Open Market | 3,000 | $70K | 12/13/2022 | View on chart |
| QURE | ▲ Buy | Option Exercise | 6,200 | — | 11/29/2022 | View on chart |
| QURE | ▼ Sell | Open Market | 6,200 | $157K | 11/29/2022 | View on chart |
| QURE | ▲ Buy | Grant | 9,080 | $0 | 6/15/2022 | View on chart |
| QURE | ▼ Sell | Open Market | 596 | $10K | 2/28/2022 | View on chart |
| QURE | ▲ Buy | Grant | 1,534 | $0 | 2/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
DNTH Highlighted by Benzinga and Announces Nasdaq Inducement Grants
Dianthus Therapeutics was named one of the top three health‑care stocks in a recent Benzinga feature that looks at companies that could help improve a portfolio this quarter. The company also disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4), a filing that relates to compliance with Nasdaq’s listing standards. Both items raise the company’s public profile and address regulatory requirements.
DNTH Highlighted by Benzinga and Announces Nasdaq Inducement Grants. Dianthus Therapeutics was named one of the top three health‑care stocks in a recent Benzinga feature that looks at companies that could help improve a portfolio this quarter. The company also disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4), a filing that relates to compliance with Nasdaq’s listing standards. Both items raise the company’s public profile and address regulatory requirements.